VAN-TELMISARTAN-HCTZ TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

TELMISARTAN; HYDROCHLOROTHIAZIDE

제공처:

VANC PHARMACEUTICALS INC

ATC 코드:

C09DA07

INN (국제 이름):

TELMISARTAN AND DIURETICS

복용량:

80MG; 12.5MG

약제 형태:

TABLET

구성:

TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 12.5MG

관리 경로:

ORAL

패키지 단위:

28/30/100

처방전 유형:

Prescription

치료 영역:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

제품 요약:

Active ingredient group (AIG) number: 0244783001; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2019-07-31

제품 특성 요약

_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 1 of 53_
PRODUCT MONOGRAPH
Pr
VAN-TELMISARTAN-HCTZ
Telmisartan / Hydrochlorothiazide Tablets
80 mg/12.5 mg and 80 mg/25 mg
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker/Diuretic
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Building 152, 11782 River Road
Richmond, BC V6X 1Z7
www.vancpharm.com
Date of Preparation:
November 7, 2014
Submission Control No: 179134
_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
...............................................................................................
11
DRUG INTERACTIONS
................................................................................................
21
DOSAGE AND ADMINISTRATION
...........................................................................
25
OVERDOSAGE
...............................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 28
STORAGE AND STABILITY
.......................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 34
PART II: SCIENTIFIC INFORMATION
.......................................................................
35
PHARMACEUTICAL INFORMATION
.....................................................................
35
CLINICAL TRIALS
.......................